Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 2018323

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2018323

Intracranial Aneurysm Market Size, Share & Trends Analysis Report By Product Type, (Surgical Clipping, Endovascular Coiling, Flow Diverters), By End-use (Hospitals, Clinics), By Aneurysm Type, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 110 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Intracranial Aneurysm Market Summary

The global intracranial aneurysm market size was estimated at USD 1.71 billion in 2025 and is projected to reach USD 3.50 billion by 2033, growing at a CAGR of 8.58% from 2026 to 2033. The growth is primarily driven by the increasing prevalence of cerebrovascular disorders, including hypertension and atherosclerosis, which are major risk factors for aneurysm formation.

Advances in medical technology, particularly in endovascular interventions such as coil embolization and flow diverters, have improved treatment outcomes and reduced procedural risks, encouraging wider adoption. In addition, the development of minimally invasive surgical devices and image-guided neurosurgical systems has facilitated earlier detection and treatment, further boosting market demand.

The growing prevalence of brain aneurysms is a key driver of the intracranial aneurysm market. As the number of patients affected by cerebrovascular disorders, hypertension, smoking, and other lifestyle-related risk factors rises, the demand for early diagnosis and effective treatment solutions increases. This is further supported by the aging global population, which is more susceptible to aneurysm formation and rupture. Early detection through advanced imaging techniques, coupled with minimally invasive treatment options like endovascular coiling and flow diversion, has expanded the patient pool seeking intervention, thereby fueling market growth. Additionally, increasing awareness among clinicians and patients about the risks associated with untreated brain aneurysms contributes to higher adoption of therapeutic procedures, making brain aneurysms a central factor driving the market. According to the Hereditary Brain Aneurysm Support 2025, unruptured brain aneurysms, localized bulges or swellings in the brain's blood vessels, are relatively common, affecting about 3% of the UK population, or roughly 2 million people. While most aneurysms remain asymptomatic and do not cause problems, a small number, between 3,000 and 5,000 cases each year, rupture, with approximately half of these resulting in fatal outcomes.

Global Intracranial Aneurysm Market Report Segmentation

This report forecasts revenue growth at country and states level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global intracranial aneurysm market report based on product type, aneurysm type, end use, and region:

  • Product Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Surgical Clipping
  • Endovascular Coiling
  • Flow Diverters
  • Others
  • Aneurysm Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Ruptured Intracranial Aneurysms
  • Unruptured Intracranial Aneurysms
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Clinics
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68038-416-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Third Party Perspective
    • 1.3.6. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights Outlook

Chapter 3. Intracranial Aneurysm Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Ancillary market outlook
  • 3.2. User Perspective Analysis
    • 3.2.1. Consumer behavior analysis
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Rising detection of unruptured aneurysms
      • 3.3.1.2. Measurable disease burden from hemorrhagic stroke/subarachnoid hemorrhage (SAH)
      • 3.3.1.3. Wider clinical adoption of endovascular technologies
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Uncertainty about natural history and rupture risk for many small, incidentally found UIAs
      • 3.3.2.2. Procedural safety constraints and periprocedural therapy requirements
    • 3.3.3. Market Opportunity Analysis
      • 3.3.3.1. Improved imaging & AI-assisted screening to systematically find missed aneurysms
      • 3.3.3.2. Expanding clinical indications for flow diversion and adjunct techniques
      • 3.3.3.3. Aging populations and increased neuroimaging for other diseases
    • 3.3.4. Market Challenges Analysis
      • 3.3.4.1. Access, disparities and real-world outcomes variance
      • 3.3.4.2. Clinical decision complexity and guideline heterogeneity
  • 3.4. Intracranial Aneurysm Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape

Chapter 4. Intracranial Aneurysm Market: Product Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Product Type Market Share, 2021 & 2033
  • 4.3. Segment Dashboard
  • 4.4. Global Intracranial Aneurysm Market by Product Type Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following:
  • 4.6. Surgical Clipping
    • 4.6.1. Surgical clipping market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Surgical clipping market procedure volume estimates and forecasts, 2021 - 2033
  • 4.7. Endovascular Coiling
    • 4.7.1. Endovascular coiling market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.7.2. Endovascular coiling market procedure volume estimates and forecasts, 2021 - 2033
  • 4.8. Flow Diverters
    • 4.8.1. Flow diverters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.8.2. Flow diverters market procedure volume estimates and forecasts, 2021 - 2033
  • 4.9. Others
    • 4.9.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Intracranial Aneurysm Market: Aneurysm Type Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Aneurysm Type Market Share, 2021 & 2033
  • 5.3. Segment Dashboard
  • 5.4. Global Intracranial Aneurysm Market by Aneurysm Type Outlook
  • 5.5. Procedural Volume
  • 5.6. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following:
  • 5.7. Ruptured intracranial aneurysms
    • 5.7.1. Ruptured intracranial aneurysms market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.8. Unruptured intracranial aneurysms
    • 5.8.1. Unruptured intracranial aneurysms market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Intracranial Aneurysm Market: End Use Estimates & Trend Analysis

  • 6.1. Definitions and Scope
  • 6.2. End Use Market Share, 2021 & 2033
  • 6.3. Segment Dashboard
  • 6.4. Global Intracranial Aneurysm Market by End Use Outlook
  • 6.5. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following:
  • 6.6. Hospitals
    • 6.6.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Clinics
    • 6.7.1. Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Intracranial Aneurysm Market: Regional Estimates & Trend Analysis By Aneurysm Type, By End Use

  • 7.1. Regional market share analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Regional Market Share and Leading Players, 2025
    • 7.4.1. North America
    • 7.4.2. Europe
    • 7.4.3. Asia Pacific
    • 7.4.4. Latin America
    • 7.4.5. Middle East and Africa
  • 7.5. Market Size & Forecasts, and Trend Analysis, 2021 TO 2033:
  • 7.6. North America
    • 7.6.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
    • 7.6.2. U.S.
      • 7.6.2.1. Key country dynamics
        • 7.6.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.6.2.1.1.1. Incidence Analysis
          • 7.6.2.1.1.2. Prevalence Analysis
          • 7.6.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. U.S. market estimates and forecasts, 2021 - 2033
    • 7.6.3. Canada
      • 7.6.3.1. Key country dynamics
        • 7.6.3.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.6.3.1.1.1. Incidence Analysis
          • 7.6.3.1.1.2. Prevalence Analysis
          • 7.6.3.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. Canada market estimates and forecasts, 2021 - 2033
    • 7.6.4. Mexico
      • 7.6.4.1. Key country dynamics
        • 7.6.4.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.6.4.1.1.1. Incidence Analysis
          • 7.6.4.1.1.2. Prevalence Analysis
          • 7.6.4.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Reimbursement scenario
      • 7.6.4.5. Mexico market estimates and forecasts, 2021 - 2033
  • 7.7. Europe
    • 7.7.1. Germany
      • 7.7.1.1. Key country dynamics
        • 7.7.1.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.7.1.1.1.1. Incidence Analysis
          • 7.7.1.1.1.2. Prevalence Analysis
          • 7.7.1.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Reimbursement scenario
      • 7.7.1.5. Germany market estimates and forecasts, 2021 - 2033
    • 7.7.2. UK
      • 7.7.2.1. Key country dynamics
        • 7.7.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.7.2.1.1.1. Incidence Analysis
          • 7.7.2.1.1.2. Prevalence Analysis
          • 7.7.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. UK market estimates and forecasts, 2021 - 2033
    • 7.7.3. France
      • 7.7.3.1. Key country dynamics
        • 7.7.3.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.7.3.1.1.1. Incidence Analysis
          • 7.7.3.1.1.2. Prevalence Analysis
          • 7.7.3.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. France market estimates and forecasts, 2021 - 2033
    • 7.7.4. Italy
      • 7.7.4.1. Key country dynamics
        • 7.7.4.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.7.4.1.1.1. Incidence Analysis
          • 7.7.4.1.1.2. Prevalence Analysis
          • 7.7.4.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement scenario
      • 7.7.4.5. Italy market estimates and forecasts, 2021 - 2033
    • 7.7.5. Spain
      • 7.7.5.1. Key country dynamics
        • 7.7.5.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.7.5.1.1.1. Incidence Analysis
          • 7.7.5.1.1.2. Prevalence Analysis
          • 7.7.5.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement scenario
      • 7.7.5.5. Spain market estimates and forecasts, 2021 - 2033
    • 7.7.6. Denmark
      • 7.7.6.1. Key country dynamics
        • 7.7.6.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.7.6.1.1.1. Incidence Analysis
          • 7.7.6.1.1.2. Prevalence Analysis
          • 7.7.6.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.7.6.2. Competitive scenario
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Reimbursement scenario
      • 7.7.6.5. Denmark market estimates and forecasts, 2021 - 2033
    • 7.7.7. Sweden
      • 7.7.7.1. Key country dynamics
        • 7.7.7.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.7.7.1.1.1. Incidence Analysis
          • 7.7.7.1.1.2. Prevalence Analysis
          • 7.7.7.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.7.7.2. Competitive scenario
      • 7.7.7.3. Regulatory framework
      • 7.7.7.4. Reimbursement scenario
      • 7.7.7.5. Sweden market estimates and forecasts, 2021 - 2033
    • 7.7.8. Norway
      • 7.7.8.1. Key country dynamics
        • 7.7.8.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.7.8.1.1.1. Incidence Analysis
          • 7.7.8.1.1.2. Prevalence Analysis
          • 7.7.8.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.7.8.2. Competitive scenario
      • 7.7.8.3. Regulatory framework
      • 7.7.8.4. Reimbursement scenario
      • 7.7.8.5. Norway market estimates and forecasts, 2021 - 2033
  • 7.8. Asia Pacific
    • 7.8.1. China
      • 7.8.1.1. Key country dynamics
        • 7.8.1.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.8.1.1.1.1. Incidence Analysis
          • 7.8.1.1.1.2. Prevalence Analysis
          • 7.8.1.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Reimbursement scenario
      • 7.8.1.5. China market estimates and forecasts, 2021 - 2033
    • 7.8.2. Japan
      • 7.8.2.1. Key country dynamics
        • 7.8.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.8.2.1.1.1. Incidence Analysis
          • 7.8.2.1.1.2. Prevalence Analysis
          • 7.8.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Reimbursement scenario
      • 7.8.2.5. Japan market estimates and forecasts, 2021 - 2033
    • 7.8.3. India
      • 7.8.3.1. Key country dynamics
        • 7.8.3.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.8.3.1.1.1. Incidence Analysis
          • 7.8.3.1.1.2. Prevalence Analysis
          • 7.8.3.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Reimbursement scenario
      • 7.8.3.5. India market estimates and forecasts, 2021 - 2033
    • 7.8.4. Australia
      • 7.8.4.1. Key country dynamics
        • 7.8.4.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.8.4.1.1.1. Incidence Analysis
          • 7.8.4.1.1.2. Prevalence Analysis
          • 7.8.4.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Reimbursement scenario
      • 7.8.4.5. Australia market estimates and forecasts, 2021 - 2033
    • 7.8.5. South Korea
      • 7.8.5.1. Key country dynamics
        • 7.8.5.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.8.5.1.1.1. Incidence Analysis
          • 7.8.5.1.1.2. Prevalence Analysis
          • 7.8.5.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.8.5.2. Competitive scenario
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Reimbursement scenario
      • 7.8.5.5. South Korea market estimates and forecasts, 2021 - 2033
    • 7.8.6. Thailand
      • 7.8.6.1. Key country dynamics
        • 7.8.6.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.8.6.1.1.1. Incidence Analysis
          • 7.8.6.1.1.2. Prevalence Analysis
          • 7.8.6.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.8.6.2. Competitive scenario
      • 7.8.6.3. Regulatory framework
      • 7.8.6.4. Reimbursement scenario
      • 7.8.6.5. Thailand market estimates and forecasts, 2021 - 2033
  • 7.9. Latin America
    • 7.9.1. Brazil
      • 7.9.1.1. Key country dynamics
        • 7.9.1.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.9.1.1.1.1. Incidence Analysis
          • 7.9.1.1.1.2. Prevalence Analysis
          • 7.9.1.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.9.1.2. Competitive scenario
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. Reimbursement scenario
      • 7.9.1.5. Brazil market estimates and forecasts, 2021 - 2033
    • 7.9.2. Argentina
      • 7.9.2.1. Key country dynamics
        • 7.9.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.9.2.1.1.1. Incidence Analysis
          • 7.9.2.1.1.2. Prevalence Analysis
          • 7.9.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.9.2.2. Competitive scenario
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Reimbursement scenario
      • 7.9.2.5. Argentina market estimates and forecasts, 2021 - 2033
  • 7.10. MEA
    • 7.10.1. South Africa
      • 7.10.1.1. Key country dynamics
        • 7.10.1.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.10.1.1.1.1. Incidence Analysis
          • 7.10.1.1.1.2. Prevalence Analysis
          • 7.10.1.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.10.1.2. Competitive scenario
      • 7.10.1.3. Regulatory framework
      • 7.10.1.4. Reimbursement scenario
      • 7.10.1.5. South Africa market estimates and forecasts, 2021 - 2033
    • 7.10.2. Saudi Arabia
      • 7.10.2.1. Key country dynamics
        • 7.10.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.10.2.1.1.1. Incidence Analysis
          • 7.10.2.1.1.2. Prevalence Analysis
          • 7.10.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.10.2.2. Competitive scenario
      • 7.10.2.3. Regulatory framework
      • 7.10.2.4. Reimbursement scenario
      • 7.10.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
    • 7.10.3. UAE
      • 7.10.3.1. Key country dynamics
        • 7.10.3.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.10.3.1.1.1. Incidence Analysis
          • 7.10.3.1.1.2. Prevalence Analysis
          • 7.10.3.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.10.3.2. Competitive scenario
      • 7.10.3.3. Regulatory framework
      • 7.10.3.4. Reimbursement scenario
      • 7.10.3.5. UAE market estimates and forecasts, 2021 - 2033
    • 7.10.4. Kuwait
      • 7.10.4.1. Key country dynamics
        • 7.10.4.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
          • 7.10.4.1.1.1. Incidence Analysis
          • 7.10.4.1.1.2. Prevalence Analysis
          • 7.10.4.1.1.3. Diagnosed vs Undiagnosed Population Assessment
      • 7.10.4.2. Competitive scenario
      • 7.10.4.3. Regulatory framework
      • 7.10.4.4. Reimbursement scenario
      • 7.10.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
    • 8.2.1. Innovators
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2025
    • 8.3.4. Stryker
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Medtronic
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. MicroPort Scientific Corporation.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Johnson and Johnson
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Terumo Corporation
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Penumbra, Inc. (Boston Scientific Corporation)
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. BAL-T Group (Balt Extrusion SAS)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. phenox GmbH ( Wallaby)
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Acandis GmbH
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. KANEKA CORPORATION
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
Show more
Product Code: GVR-4-68038-416-1

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global intracranial aneurysm market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 5 Global intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 6 Global intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 7 North America intracranial aneurysm market, by region, 2021 - 2033 (USD Million)
  • Table 8 North America intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 9 North America intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 10 North America intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 11 U.S. intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 12 U.S. intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 13 U.S. intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 14 U.S. intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Canada intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 16 Canada intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 17 Canada intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 18 Mexico intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 19 Mexico intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 20 Mexico intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Europe intracranial aneurysm market, by region, 2021 - 2033 (USD Million)
  • Table 22 Europe intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 23 Europe intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 24 Europe intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 25 UK intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 26 UK intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 27 UK intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Germany intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 29 Germany intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 30 Germany intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 31 France intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 32 France intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 33 France intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Italy intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 35 Italy intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 36 Italy intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Spain intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 38 Spain intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 39 Spain intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Denmark intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 41 Denmark intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 42 Denmark intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Sweden intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 44 Sweden intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 45 Sweden intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific intracranial aneurysm market, by region, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Japan intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 51 Japan intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 52 Japan intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 53 China intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 54 China intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 55 China Sweden intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 56 India intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 57 India intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 58 India intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Australia intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 60 Australia intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 61 Australia intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Thailand intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 63 Thailand intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 64 Thailand intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 65 South Korea intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 66 South Korea intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 67 South Korea intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 68 Latin America intracranial aneurysm market, by region, 2021 - 2033 (USD Million)
  • Table 69 Latin America intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 70 Latin America intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 71 Latin America intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 72 Brazil intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 73 Brazil intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 74 Brazil intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 75 Argentina intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 76 Argentina intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 77 Argentina intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 78 Middle East and Africa intracranial aneurysm market, by region, 2021 - 2033 (USD Million)
  • Table 79 Middle East and Africa intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 80 Middle East and Africa intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 81 Middle East and Africa intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 82 South Africa intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 83 South Africa intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 84 South Africa intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 88 UAE intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 89 UAE intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 90 UAE intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Kuwait intracranial aneurysm market, by product type, 2021 - 2033 (USD Million)
  • Table 92 Kuwait intracranial aneurysm market, by aneurysm type, 2021 - 2033 (USD Million)
  • Table 93 Kuwait intracranial aneurysm market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Intracranial aneurysm: Market outlook
  • Fig. 8 Intracranial aneurysm: Competitive insights
  • Fig. 9 Ancillary market outlook
  • Fig. 10 Industry value chain analysis
  • Fig. 11 Intracranial aneurysm market driver impact
  • Fig. 12 Intracranial aneurysm market restraint impact
  • Fig. 13 Intracranial aneurysm market: Product type movement analysis
  • Fig. 14 Intracranial aneurysm market: Product type outlook and key takeaways
  • Fig. 15 Surgical clipping market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 Endovascular coiling market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Flow diverters market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Intracranial aneurysm market: Aneurysm type movement analysis
  • Fig. 20 Intracranial aneurysm market: Aneurysm type outlook and key takeaways
  • Fig. 21 Ruptured intracranial aneurysms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Unruptured intracranial aneurysms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Intracranial aneurysm market: End Use movement analysis
  • Fig. 24 Intracranial aneurysm market: End use outlook and key takeaways
  • Fig. 25 Hospitals market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Clinics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Global intracranial aneurysm market: Regional movement analysis
  • Fig. 29 Global intracranial aneurysm market: Regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Middle East and Africa. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!